Previous 10 | Next 10 |
Shares of DURECT Corporation (NASDAQ:DRRX) traded today at $1.30, breaking its 52-week low. This new low was reached on below average trading volume as 117,000 shares traded hands, while the average 30-day volume is approximately 609,000 shares. In the past 52 weeks, shares of DURECT Cor...
DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit PR Newswire CUPERTINO, Calif. , July 14, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will present at the Epigenetic Therapeutic Targets Sum...
DURECT Corporation (NASDAQ:DRRX) traded at a new 52-week low today of $1.35. This new low was reached on below average trading volume as 117,000 shares traded hands, while the average 30-day volume is approximately 604,000 shares. DURECT Corporation has overhead space with shares priced ...
DURECT Corporation (NASDAQ:DRRX) traded at a new 52-week low today of $1.40. So far today approximately 117,000 shares have been exchanged, as compared to an average 30-day volume of 601,000 shares. DURECT Corporation share prices have moved between a 52-week high of $2.95 and the curren...
Shares of DURECT Corporation (NASDAQ:DRRX) traded today at $1.41, breaking its 52-week low. This new low was reached on below average trading volume as 117,000 shares traded hands, while the average 30-day volume is approximately 632,000 shares. Durect Corp is a biopharmaceutical company...
DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL) New Data Further Supports DUR-928's Potential in Acute and Chronic as well as Moderate and Severe Li...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL) PR Newswire CUPERTINO, Calif. , June 9, 2021 /PRNewswire/ -- DURECT Corpora...
DURECT Corporation (DRRX) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants Mike Arenberg – Chief Financial Officer Jim Brown – President and Chief Executive Officer WeiQi Lin – Executive Vice President-Research and Development, Principal Scient...
DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs Webcast of Earnings Call Today, May 4th at 4:30 p.m. ET PR Newswire CUPERTINO, Calif. , May 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced ...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...